NEWPORT BEACH, Calif.,
Feb. 25, 2021 /PRNewswire/ -- Vivera
Pharmaceuticals, Inc., is pleased to announce the expansion of its
exclusive global licensing of the novel TABMELT® platform to
Russia. The latest TABMELT® patent
approval comes as the Company begins to expand its pharmaceutical
offerings into neuroscience, and joins Canada, the United
Kingdom, and Australia as
countries that have granted patent rights to the TABMELT®
sublingual technology.
"With the finalization and granting of the long-awaited Russian
patent, TABMELT® has an even stronger international presence,"
states Paul Edalat, CEO of Vivera
Pharmaceuticals. "With Vivera's exclusive global license of the
TABMELT® technology for use in pharmaceuticals, we are able to
develop better medications for patients at home and abroad. We look
forward to strengthening our ties with our Eastern European
partners and working closely together."
Internationally patented and U.S. patent-pending,
TABMELT® may optimize delivery of active pharmaceutical
ingredients (API's) by offering a sublingual, precision-dose system
which may enhance bioavailability by largely avoiding first-pass
metabolism through the liver.
"Sublingual delivery of medication has been vastly
underused. The advantages of precision dosing is that
providers are able to dial in dosages based on patient's
needs," says Dr. Stephen
McColgan, Vivera Pharmaceuticals' Chief Medical Officer. "At
Vivera, we plan to pioneer many innovative medications via the
TABMELT® delivery system."
Currently, Vivera is preparing for clinical studies utilizing
TABMELT® in the development of its neurosciences offerings. The
Company hopes to announce the launch of new therapeutics for the
treatment of psychiatric disorders this year.
About Vivera Pharmaceuticals, Inc.
Vivera Pharmaceuticals, Inc., is an innovative, science-driven
pharmaceutical company focused on novel therapies for a variety of
indications. In addition to its pharmaceutical, medical device,
advanced diagnostics, medical supply, medical technologies,
neurosciences, and health and human service divisions, the Company
has global exclusivity to license the patented and patent-pending
TABMELT® sublingual drug-delivery system for the
pharmaceutical use of therapeutic compounds. Vivera is vertically
integrated with patented technology, manufacturing capabilities,
and distribution for its products. For more information please
visit www.viverapharma.com.
MEDIA CONTACT
Cerrell
Brandon Stephenson
310-795-3142
brandon@cerrell.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/tabmelt-granted-patent-rights-in-russia-expanding-vivera-global-licensing-301235715.html
SOURCE Vivera Pharmaceuticals, Inc.